InvestorsHub Logo
Followers 51
Posts 9111
Boards Moderated 1
Alias Born 10/25/2007

Re: Talc Moan post# 12447

Friday, 02/17/2023 12:08:29 AM

Friday, February 17, 2023 12:08:29 AM

Post# of 13489
Moderna said it has already updated mRNA-1010 in a way it believes will improve immune responses against Influenza B and will test those changes.

The first per protocol interim analysis of efficacy is now expected to be reviewed by an independent Data and Safety Monitoring Board (DSMB) before the end of the first quarter. Based on these results the DSMB will notify the Company whether the primary efficacy endpoint has been met or whether the study should continue accruing further cases towards the final analysis.


That’s the beauty of live


relax$
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News